ACS Medicinal Chemistry Letters最新文献_第7页

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-12

Javier L. Baylon*, Matthew J. Chalkley, Tony Siu, Wilson Shou, Yongnian Sun, Xianmei Cai, Anthony Paiva, Shivani Patel, Tatyana Zvyaga and Dahlia R. Weiss,

引用次数: 0

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-12

Robert B. Kargbo*,

引用次数: 0

Novel Substituted Pyrazoles as 5-HT1A Agonists for Treating Neuropsychiatric Diseases 新型取代吡唑作为5-HT1A激动剂治疗神经精神疾病

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 DOI: 10.1021/acsmedchemlett.5c0030610.1021/acsmedchemlett.5c00306

Ram W. Sabnis*,

引用次数: 0

Novel Substituted Pyrazoles as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases. 新型取代吡唑作为5‑HT1A激动剂治疗神经精神疾病

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 eCollection Date: 2025-06-12 DOI: 10.1021/acsmedchemlett.5c00306

Ram W Sabnis

引用次数: 0

Suzuki–Miyaura Coupling of Pinacolboronic Esters Catalyzed by a Well-Defined Palladium N-Heterocyclic Carbene (NHC) Catalyst 一种定义良好的n -杂环钯（NHC）催化剂催化的双硼酸酯的Suzuki-Miyaura偶联

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 DOI: 10.1021/acsmedchemlett.5c0020610.1021/acsmedchemlett.5c00206

Aleksei A. Logvinov, Geert Rombouts, Matthieu Jouffroy* and Steven P. Nolan*,

引用次数: 0

Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype 吡咯喹诺酮类化合物作为一种新型抗细菌化学型

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 DOI: 10.1021/acsmedchemlett.5c0018310.1021/acsmedchemlett.5c00183

Marta Clariano, Diogo Nunes, Daniela Canudo, Daniela Maçãs, Bruno J. L. Castro, Audrey Jordaan, Pedro Gomes, Anna Contini, João Perdigão, Isabel Portugal, Margarida Madureira, Digby F. Warner, Marco Pieroni, Maria de Jesus Perry* and Francisca Lopes*,

{"title":"Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype","authors":"Marta Clariano, Diogo Nunes, Daniela Canudo, Daniela Maçãs, Bruno J. L. Castro, Audrey Jordaan, Pedro Gomes, Anna Contini, João Perdigão, Isabel Portugal, Margarida Madureira, Digby F. Warner, Marco Pieroni, Maria de Jesus Perry* and Francisca Lopes*, ","doi":"10.1021/acsmedchemlett.5c0018310.1021/acsmedchemlett.5c00183","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00183https://doi.org/10.1021/acsmedchemlett.5c00183","url":null,"abstract":"Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), remains the world’s most lethal infectious disease, posing an uncontained health challenge. The major hurdles are the long treatments and low patient compliance that leads to the appearance of resistance, as well as the lack of drugs that effectively tackle the latent infections. Herein we report the development of compounds with the ability to target the electron transport chain of Mtb by inhibiting cytochrome bcc (cyt-bcc) (7a–i) and additionally being capable of inhibiting cytochrome bd (cyt-bd) (7j and 7k). We present the synthesis, determination of physicochemical properties, evaluation of the antibacterial activity, and cytotoxicity assessment of pyrroloquinolone-based compounds. The antibacterial evaluation of 7a–k showed selectivity toward mycobacteria, and the results identify cyt-bcc as their target. Compounds 7j and 7k presented promising results against Mtb and good physicochemical properties. Cytotoxicity assays revealed a good safety profile regarding the toxicity for human cell lines.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"1139–1146 1139–1146"},"PeriodicalIF":3.5,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional Degraders 新的多参数指标是异双功能降解剂口服生物利用度的有力预测指标

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 DOI: 10.1021/acsmedchemlett.5c0015610.1021/acsmedchemlett.5c00156

Javier L. Baylon*, Matthew J. Chalkley, Tony Siu, Wilson Shou, Yongnian Sun, Xianmei Cai, Anthony Paiva, Shivani Patel, Tatyana Zvyaga and Dahlia R. Weiss,

{"title":"New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional Degraders","authors":"Javier L. Baylon*, Matthew J. Chalkley, Tony Siu, Wilson Shou, Yongnian Sun, Xianmei Cai, Anthony Paiva, Shivani Patel, Tatyana Zvyaga and Dahlia R. Weiss, ","doi":"10.1021/acsmedchemlett.5c0015610.1021/acsmedchemlett.5c00156","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00156https://doi.org/10.1021/acsmedchemlett.5c00156","url":null,"abstract":"Ligand-directed degraders (LDDs) are heterobifunctional molecules that degrade proteins by engaging the ubiquitin-protein-ligase (E3) system. LDDs (also known as proteolysis-targeting chimeras) consist of a target-engaging moiety, an E3 ligase-binding moiety, and a bridging linker. Due to their size and physicochemical complexity, these molecules do not adhere to well-established rules of lead optimization. Achieving oral bioavailability remains a key challenge in the optimization of LDDs as therapeutic agents. In this study, we build on the previously established Balanced Permeability Index (BPI) (a metric that integrates size, polarity, and lipophilicity) by incorporating an additional descriptor to account for molecular shape. Our new combined metric, termed Bifunctional Bioavailability Index (BBI), can differentiate oral bioavailability of LDDs in our data set more effectively than polarity, lipophilicity, or size separately. Notably, BBI is also more effective than in vitro cell permeability assays in predicting orally bioavailable LDDs. These results support the use of BBI as a computational tool for designing and optimizing bioavailable bifunctional degraders.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"1108–1113 1108–1113"},"PeriodicalIF":3.5,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional Degraders. 新的多参数指标是异双功能降解剂口服生物利用度的有力预测指标。

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 eCollection Date: 2025-06-12 DOI: 10.1021/acsmedchemlett.5c00156

Javier L Baylon, Matthew J Chalkley, Tony Siu, Wilson Shou, Yongnian Sun, Xianmei Cai, Anthony Paiva, Shivani Patel, Tatyana Zvyaga, Dahlia R Weiss

{"title":"New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional Degraders.","authors":"Javier L Baylon, Matthew J Chalkley, Tony Siu, Wilson Shou, Yongnian Sun, Xianmei Cai, Anthony Paiva, Shivani Patel, Tatyana Zvyaga, Dahlia R Weiss","doi":"10.1021/acsmedchemlett.5c00156","DOIUrl":"10.1021/acsmedchemlett.5c00156","url":null,"abstract":"Ligand-directed degraders (LDDs) are heterobifunctional molecules that degrade proteins by engaging the ubiquitin-protein-ligase (E3) system. LDDs (also known as proteolysis-targeting chimeras) consist of a target-engaging moiety, an E3 ligase-binding moiety, and a bridging linker. Due to their size and physicochemical complexity, these molecules do not adhere to well-established rules of lead optimization. Achieving oral bioavailability remains a key challenge in the optimization of LDDs as therapeutic agents. In this study, we build on the previously established Balanced Permeability Index (BPI) (a metric that integrates size, polarity, and lipophilicity) by incorporating an additional descriptor to account for molecular shape. Our new combined metric, termed Bifunctional Bioavailability Index (BBI), can differentiate oral bioavailability of LDDs in our data set more effectively than polarity, lipophilicity, or size separately. Notably, BBI is also more effective than in vitro cell permeability assays in predicting orally bioavailable LDDs. These results support the use of BBI as a computational tool for designing and optimizing bioavailable bifunctional degraders.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"1108-1113"},"PeriodicalIF":3.5,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suzuki-Miyaura Coupling of Pinacolboronic Esters Catalyzed by a Well-Defined Palladium N‑Heterocyclic Carbene (NHC) Catalyst. 一种定义良好的N杂环钯（NHC）催化剂催化的双硼酸酯的Suzuki-Miyaura偶联。

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 eCollection Date: 2025-06-12 DOI: 10.1021/acsmedchemlett.5c00206

Aleksei A Logvinov, Geert Rombouts, Matthieu Jouffroy, Steven P Nolan

引用次数: 0

Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype. 吡咯喹诺酮类化合物作为一种新型抗细菌化学型。

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2025-06-03 eCollection Date: 2025-06-12 DOI: 10.1021/acsmedchemlett.5c00183

Marta Clariano, Diogo Nunes, Daniela Canudo, Daniela Maçãs, Bruno J L Castro, Audrey Jordaan, Pedro Gomes, Anna Contini, João Perdigão, Isabel Portugal, Margarida Madureira, Digby F Warner, Marco Pieroni, Maria de Jesus Perry, Francisca Lopes

{"title":"Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype.","authors":"Marta Clariano, Diogo Nunes, Daniela Canudo, Daniela Maçãs, Bruno J L Castro, Audrey Jordaan, Pedro Gomes, Anna Contini, João Perdigão, Isabel Portugal, Margarida Madureira, Digby F Warner, Marco Pieroni, Maria de Jesus Perry, Francisca Lopes","doi":"10.1021/acsmedchemlett.5c00183","DOIUrl":"10.1021/acsmedchemlett.5c00183","url":null,"abstract":"Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), remains the world's most lethal infectious disease, posing an uncontained health challenge. The major hurdles are the long treatments and low patient compliance that leads to the appearance of resistance, as well as the lack of drugs that effectively tackle the latent infections. Herein we report the development of compounds with the ability to target the electron transport chain of Mtb by inhibiting cytochrome bcc (cyt-bcc) (7a-i) and additionally being capable of inhibiting cytochrome bd (cyt-bd) (7j and 7k). We present the synthesis, determination of physicochemical properties, evaluation of the antibacterial activity, and cytotoxicity assessment of pyrroloquinolone-based compounds. The antibacterial evaluation of 7a-k showed selectivity toward mycobacteria, and the results identify cyt-bcc as their target. Compounds 7j and 7k presented promising results against Mtb and good physicochemical properties. Cytotoxicity assays revealed a good safety profile regarding the toxicity for human cell lines.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 6","pages":"1139-1146"},"PeriodicalIF":3.5,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0